Skip to main content
Premium Trial:

Request an Annual Quote

Michael Fitzgerald

Premium

Sequenom board member Michael Fitzgerald resigned last week after complaining that the firm clouded how and why he left. Fitzgerald, who has been on the firm’s board since it acquired Gemini Genomics in Spetember 2001, said he was pushed out; Sequenom maintains he was simply not renominated.

In his May 14 letter, which appears in Sequenom’s proxy statement, Fitzgerald writes “it had become increasingly apparent to me that the board of Sequenom had ceased properly to exercise its oversight function and challenge management. The failure of the board to subject management performance and planning to appropriate scrutiny represents a serious lack of accountability to an extent that is contrary to the best interests of the shareholders. My own efforts to reverse this trend received no effective support by the other members of the board and were increasingly quite openly shrugged off as an inconvenience and an intrusion, ultimately leading to the proposal that I not be re-nominated.”

Responding to Fitzgerald’s letter, Sequenom writes in its proxy that it “agrees with Mr. Fitzgerald's self-assessment in his letter that he has been very critical of [the company’s] management during his tenure as a director but does not agree with his conclusions or the allegations or characterizations expressed in his letter.”

Filed under

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.